Jeffrey A. Borgia, PhD, is a graduate of the Biochemistry Graduate program at the University of Minnesota where he performed research in the field of proteoglycan biosynthesis in the laboratory of Dr. Theodore R. Oegema, Jr. During his post-doctoral studies, he collaborated with Dr. Gregg B. Fields where he explored the production of matrix metalloproteinases by melanoma cells when adhered to synthetic ‘mini-collagens’ as well as tumor cell aggressiveness. In 2002, Dr. Borgia joined the faculty at Rush in the Department of Biochemistry and launched his program focused on cancer biology and the development of novel diagnostic tests with Dr. John S. Coon, IV in the Department of Pathology. He is currently continuing these studies with appointments in both the Department of Anatomy & Cell Biology and Department of Pathology.
Our work
- Development of novel serum biomarkers as companion diagnostics for lung cancer screening programs for the promotion the early detection of lung cancer.
- Profile autoantibody expression related to early pulmonary malignancies and common pulmonary diseases.
- Investigate mechanisms underlying tumor metastasis to better prognosticate patient outcomes and to identify novel biochemical targets for pharmaceutical development.
- Study the mechanisms of cancer cachexia in lung cancer
- Elucidate the autoimmunity paradigm in relation to lung cancer progression and in the context of immune-checkpoint inhibition strategies provided to patients with advanced-stage disease.
- Pioneer new methods to enhance the delivery and long-term storage of blood-based (protein) biomarkers for diagnostic applications of the detection/prognosis of malignancies and pulmonary disease.
- Serological surveys of populations for Covid-19, including assessments of immunity and vaccine potency.
Technology and methods
- Agilent 6495 QQQ Mass Spectrometer with Agilent 1290 UHPLC system
- Luminex FlexMAP 3D, automated with an Agilent AssayMAP BRAVO and Biotek 405TS
- Agilent 1260 HPLC system, multidimensional for offline protein fractionation
- BioRad 1- and 2-dimensional electrophoresis workflow
Publications
Please visit the following link for a list of the publications listed on PubMed:
https://www.ncbi.nlm.nih.gov/myncbi/1viApd51LKn5A/bibliography/public/
Funding
Active Projects
- Piccolo Foundation
Role: Principal Investigator
“Proteomic Analysis of MEK and PI3K Inhibition of Patient-derived Murine Models of Breast Cancer.”
Purpose: Identify phosphoproteomic and proteomic changes in a series of patient-derived murine xenograft models in response to PI3K inhibition. - Swim Across America
Role: Co-Principal Investigator (w/ Christoper W. Seder, MD)
“Defining proteomic biomarkers associated with recurrence in early-stage non-small cell lung cancer.”
Purpose: We will use multi-Omic methods to identify (molecular) phenotypic features of early-stage lung cancer tumors to better understand and predict metastatic progression in an effort to improve treatment decisions in the adjuvant setting. - Brinson Foundation
Role: Co-Principal Investigator (w/ Melody Cobleigh, MD)
“Proteomic evaluation of apoptosis, cell cycle markers and validation of AKT/MEK Inhibition of PIK3R1-mutated and wild type patient-derived murine models of breast cancer” - Tempus AI
Role: Principal Investigator
Biorepository Resource Agreement
Purpose: Collection of a strategic cohort of cases for collaborative studies with Tempus AI. - Serum Detect, Inc.
Role: Principal Investigator
Multi-Omic Biomarkers for the Early Detection of Colorectal Cancer - Abbott Molecular
Role: Principal Investigator
Collaborative Research Agreement - Tempus AI
Role: Principal Investigator
Biostorage Agreement (Amendment)
Purpose: Collection of materials to develop a highly strategic arsenal of patient-derived tumor organoid cultures to serve as model systems for mechanistic and drug development purposes. - Serum Detect, Inc.
Role: Co-Principal Investigator (w/ Dr. Michael Liptay)
“Multi-omic biomarkers for the early detection of lung cancer”. - Abbott Molecular
Role: Principal Investigator
“Lung cancer early detection - Panel/algorithm development for indeterminate pulmonary nodule malignancy assessment”
Selection of Recently Completed Projects
- National Cancer Institute (R21) R21CA223335
“Targeted proteomics to aid in the management of patients with stage IA lung adeno”
Purpose: The goal of this project is to develop a series of biomarkers prognostic for disease recurrence in stage IA lung adenocarcinoma using targeted proteomics. - National Cancer Institute; 1 RO1 CA223490-01
Role: Principal Investigator, Rush site (Y. Deng – PI)
“Profiling genome-wide circulating ncRNAs for the early detection of lung cancer” - National Cancer Institute; 1R01 CA230778-01
Role: Principal Investigator, Rush site (T. Shimamura – PI)
“Investigation of CXCR7 signalling in EGFR TKI resistant NSCLC” - National Institutes of Health; 1 UM1-NS112874-01
Role: Consultant (J. Burns – PI)
Transition from Acute to Chronic Pain in Total Knee Arthroplasty Patients: Identifying Resilience and Vulnerability Profiles. (Mechanism RFA-RM-18-034: Multisite Clinical Center Common Fund Acute to Chronic Pain Signatures Program: Acute Peri-operative Pain (UM1 Clinical Trial Optional)) - Swim Across America
Role: Principal Investigator
“Radioproteomic profiling to improve prognostication in stage I NSCLC” - Swim Across America
Role: Co-Investigator (PI- Carl Maki)
“Targeting histone demethylases in non-small cell lung cancer” - Walder Foundation
Role: Co-Investigator (PI – Jeffrey Schneider)
“Characterizing the broadly neutralizing antibody response in SARS-CoV-2 infected individuals”
Our team
Current Research Laboratory Members
Ross Burwell, MS, PA(ASCP) (Pathologist Assistant)
David Gerard, MS (Laboratory Manager)
Martice Herron (Clinical Research Coordinator)
Akanksha Sharma, PhD (Post-Doctoral Fellow)
Kevin Little (Clinical Research Coordinator)
Kelly Cagin (Graduate Student)
Radhika Patel (Graduate Student)
Contact
Jeffrey A. Borgia, PhD
Rush University Medical Center
Jelke Southcenter, 1411A
1750 W. Harrison St.
Chicago, IL 60612
Office: (312) 942-7837
Email: jeffrey_a_borgia@rush.edu